Compare BigBearai Holdings Inc (BBAI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs 10X Genomics Inc — how do they compare? BigBearai Holdings Inc trades at $3.32 (market cap $1.55B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: 10X Genomics Inc is far larger — about 4.9× BigBearai Holdings Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | TXG | |
|---|---|---|
Market Cap | $1.55B | $7.64B |
Sector | Technology | Health |
52-Week High | $8.91 | $58.57 |
52-Week Low | $2.61 | $11.34 |
Enterprise Value | $1.25B | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.27, up 8.64% with a bullish technical signal despite negative profitability metrics. The company reported Q2 2026 revenue growth of 13% and beat EPS estimates, though it remains unprofitable with a -65.2% net income margin. Recent news highlights defense contract execution and generative AI platform expansion for government clients.
The outlook remains challenging due to persistent losses and negative cash flow from operations, though analyst consensus leans neutral with 75% hold ratings. Key risks include execution on government contracts and achieving profitability, while technical indicators suggest near-term bullish momentum.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
